clinical trial · NCT07227207
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
Tessera Therapeutics, Inc.·phase2·not yet recruiting·n = 72
Alpha-1 Antitrypsin Deficiency (AATD)TSRA-196
brief summary
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
started
Dec 1, 2025
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Nov 12, 2025
official title
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol